Get access

Vascular endothelial growth factor receptor 1 expression in nasal polyp tissue

Authors

  • S. Bobic,

    1. Laboratory of Clinical Immunology, Department of Microbiology and Immunology, Catholic University of Leuven, Leuven, Belgium
    Search for more papers by this author
  • V. Hox,

    1. Laboratory of Clinical Immunology, Department of Microbiology and Immunology, Catholic University of Leuven, Leuven, Belgium
    Search for more papers by this author
  • I. Callebaut,

    1. Laboratory of Clinical Immunology, Department of Microbiology and Immunology, Catholic University of Leuven, Leuven, Belgium
    Search for more papers by this author
  • S. Vinckier,

    1. Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center (VRC), VIB, Leuven, Belgium
    2. Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center (VRC), Catholic University of Leuven, Leuven, Belgium
    Search for more papers by this author
  • B. Jonckx,

    1. ThromboGenics NV, Leuven, Belgium
    Search for more papers by this author
  • J.-M. Stassen,

    1. ThromboGenics NV, Leuven, Belgium
    Search for more papers by this author
  • M. Jorissen,

    1. Clinical Department of Otorhinolaryngology, Head and Neck Surgery, Catholic University Hospitals, Leuven, Belgium
    Search for more papers by this author
  • P. Gevaert,

    1. Department of Oto-Rhino-Laryngology, Upper Airway Research Laboratory (URL), Ghent University Hospital, Ghent, Belgium
    Search for more papers by this author
  • P. Carmeliet,

    1. Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center (VRC), VIB, Leuven, Belgium
    2. Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center (VRC), Catholic University of Leuven, Leuven, Belgium
    Search for more papers by this author
  • C. Bachert,

    1. Department of Oto-Rhino-Laryngology, Upper Airway Research Laboratory (URL), Ghent University Hospital, Ghent, Belgium
    Search for more papers by this author
  • J. L. Ceuppens,

    1. Laboratory of Clinical Immunology, Department of Microbiology and Immunology, Catholic University of Leuven, Leuven, Belgium
    Search for more papers by this author
  • P. W. Hellings

    Corresponding author
    1. Laboratory of Clinical Immunology, Department of Microbiology and Immunology, Catholic University of Leuven, Leuven, Belgium
    2. Clinical Department of Otorhinolaryngology, Head and Neck Surgery, Catholic University Hospitals, Leuven, Belgium
    • Correspondence

      Dr. Peter Hellings, Clinical Department of Otorhinolaryngology, Head and Neck Surgery, Catholic University Hospitals, Kapucijnevoer 33, 3000 Leuven, Belgium.

      Tel.: +32-16-332342

      Fax: +32-16-343835

      E-mail: Peter.Hellings@uzleuven.be

    Search for more papers by this author

  • Edited by: Angela Haczku

Abstract

Background

Edema represents a key feature of nasal polyp (NP) disease. Members of the vascular endothelial growth factor (VEGF) family may be involved, but the precise role of VEGF-A, VEGF-B, placental growth factor (PlGF), and their receptors VEGFR1 and VEGFR2 in NP edema formation remains elusive.

Objective

Exploring the expression of VEGF family members and their receptors and their correlation with clinical, radiological, and edema markers in NP.

Methods

The expression of VEGF-A, VEGF-B, PlGF, VEGFR1, and VEGFR2 was measured in NP (n = 23) and control tissue (n = 22) at mRNA and protein level. Edema was evaluated by measuring albumin levels and wet/dry ratios. Computed tomography (CT) scans were scored using the Lund-Mackay scoring system. IL-5 mRNA expression was determined by real-time RT-PCR. Cell suspensions from NP (n = 10) and control tissue (n = 12) were stimulated in vitro with IL-1β or TNFα.

Results

mRNA expression of VEGFR1 and VEGF-B was significantly higher in NP compared with control tissue. Expression levels of VEGF-B and VEGFR1 significantly correlated with NP albumin content (VEGF-B: P = 0.0208; VEGFR1: P = 0.0293), CT scan scores (VEGF-B: P = 0.0075; VEGFR1: P = 0.0068), and IL-5 mRNA (VEGF-B: P = 0.0027; VEGFR1: P = 0.0001). In vitro stimulation of control and NP tissue cell suspensions with IL-1β or TNFα significantly reduced the expression of VEGFR2 in control tissue, without altering VEGFR1 and VEGF-B expression. hVEGF-B induced nitric oxide production in NP macrophages (P < 0.05).

Conclusion

Expression levels of VEGFR1 and VEGF-B correlate with edema and clinical markers of NP disease and therefore represent potential therapeutic targets.

Ancillary